top of page
NICU
Protocols
Ethics
Additional text associated with protocol
I am a paragraph. Click here to add text.
I am a paragraph. Click here to add text.
NICU Clinical Feeding Protocol for Infants <2000
Erythropoetin Protocol
The Many Facets of Erythropoietin Physiologic and Metabolic Response
(https://www.frontiersin.org/articles/10.3389/fphys.2019.01534/full)In mammals, erythropoietin (EPO), produced in the kidney, is essential for bone marrow erythropoiesis, and hypoxia induction of EPO production provides for the important erythropoietic response to ischemic stress, such as during blood loss and at high altitude. Erythropoietin acts by binding to its…
(https://www.frontiersin.org/articles/10.3389/fphys.2019.01534/full)FrontiersAnna Bogdanova(https://www.frontiersin.org/articles/10.3389/fphys.2019.01534/full)
The Effect of Epoetin Beta (Recombinant Human Erythropoietin) on the Need for Transfusion in Very-Low-Birth-Weight Infants | NEJM
(https://www.nejm.org/doi/full/10.1056/NEJM199404283301701)Original Article from The New England Journal of Medicine — The Effect of Epoetin Beta (Recombinant Human Erythropoietin) on the Need for Transfusion in Very-Low-Birth-Weight Infants
(https://www.nejm.org/doi/full/10.1056/NEJM199404283301701)New England Journal of MedicineRenew(https://www.nejm.org/doi/full/10.1056/NEJM199404283301701)
Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial - PubMed
(https://pubmed.ncbi.nlm.nih.gov/11581447/)The combination of early Epo and iron as administered in this study stimulated erythropoiesis in infants who were </=1250 g at birth. However, the lack of impact on transfusion requirements fails to support routine use of early Epo.neonate, intravenous iron, donor exposure.
(https://pubmed.ncbi.nlm.nih.gov/11581447/)PubMedR K Ohls(https://pubmed.ncbi.nlm.nih.gov/11581447/)
Early erythropoiesis‐stimulating agents in preterm or low birth weight infants - Ohlsson, A - 2020 | Cochrane Library
(https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004863.pub6/full)
The Cochrane Library Trusted evidence. Informed decisions. Better health.Arne Ohlsson(https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004863.pub6/full)
Late erythropoiesis‐stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants - Aher, SM - 2020 | Cochrane Library
(https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004868.pub6/full)
The Cochrane Library Trusted evidence. Informed decisions. Better health.Sanjay M Aher(https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004868.pub6/full)
Erythropoietin improves neurodevelopmental outcome of extremely preterm infants - PubMed
(https://pubmed.ncbi.nlm.nih.gov/20437563/)The results of our observational study confirm the hypothesis of a neuroprotective effect of rEpo in ELBW infants with IVH. This offers a promising preventative therapeutic option for the treatment of these high-risk infants.
(https://pubmed.ncbi.nlm.nih.gov/20437563/)PubMedAchim-Peter Neubauer(https://pubmed.ncbi.nlm.nih.gov/20437563/)
Erythropoietin concentrations and neurodevelopmental outcome in preterm infants - PubMed
(https://pubmed.ncbi.nlm.nih.gov/16908620/)Erythropoietin concentrations did not correlate with Psychomotor Development Index or overall incidence of neurodevelopmental impairment; however, infants with elevated erythropoietin concentrations had higher Mental Development Index scores than those with lower erythropoietin concentrations. Close…
(https://pubmed.ncbi.nlm.nih.gov/16908620/)PubMedRyann Bierer(https://pubmed.ncbi.nlm.nih.gov/16908620/)
Cognitive Outcomes of Preterm Infants Randomized to Darbepoetin, Erythropoietin, or Placebo
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531269/)We previously reported decreased transfusions and donor exposures in preterm infants randomized to Darbepoetin (Darbe) or erythropoietin (Epo) compared with placebo. As these erythropoiesis-stimulating agents (ESAs) have shown promise as neuroprotective ...
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531269/)PubMed Central (PMC)Robin K. Ohls(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4531269/)
A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants | NEJM
(https://www.nejm.org/doi/10.1056/NEJMoa1907423)Original Article from The New England Journal of Medicine — A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants
(https://www.nejm.org/doi/10.1056/NEJMoa1907423)New England Journal of MedicineRenew(https://www.nejm.org/doi/10.1056/NEJMoa1907423)
Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy - PubMed
(https://pubmed.ncbi.nlm.nih.gov/19651565/)Repeated, low-dose, recombinant human erythropoietin treatment reduced the risk of disability for infants with moderate HIE, without apparent side effects.
(https://pubmed.ncbi.nlm.nih.gov/19651565/)PubMedChanglian Zhu(https://pubmed.ncbi.nlm.nih.gov/19651565/)
High-Dose Erythropoietin and Hypothermia for Hypoxic-Ischemic Encephalopathy: A Phase II Trial - PubMed
(https://pubmed.ncbi.nlm.nih.gov/27244862/)High doses of Epo given with hypothermia for hypoxic-ischemic encephalopathy may result in less MRI brain injury and improved 1-year motor function.
(https://pubmed.ncbi.nlm.nih.gov/27244862/)PubMedYvonne W Wu(https://pubmed.ncbi.nlm.nih.gov/27244862/)
Systematic review seeking erythropoietin role for neuroprotection in neonates with hypoxic ischemic encephalopathy: presently where do we stand - PubMed
(https://pubmed.ncbi.nlm.nih.gov/28797191/)EPO treatment has neuroprotective effects against moderate/severe HIE and improves long-term behavioral neurological developments in neonates.
(https://pubmed.ncbi.nlm.nih.gov/28797191/)PubMedBhawandeep Garg(https://pubmed.ncbi.nlm.nih.gov/28797191/)
Update on Erythropoiesis-Stimulating Agents Administered to Neonates for Neuroprotection - PubMed
(https://pubmed.ncbi.nlm.nih.gov/31676737/)Erythropoiesis-stimulating agents (ESAs) such as erythropoietin and darbepoetin have been studied as red blood cell growth factors in preterm and term infants for more than 30 years. Recently, studies have focused on the potential neuroprotective effects of ESAs. In this review, we summarize preclin…
(https://pubmed.ncbi.nlm.nih.gov/31676737/)PubMedJessie R Maxwell(https://pubmed.ncbi.nlm.nih.gov/31676737/)
Metabolic Bone Disease of the Premature Infant
I am a paragraph. Click here to add text. It is easy.
I am a paragraph. Click here to add text. It is easy.
I am a paragraph. Click here to add text. It is easy.
I am a paragraph. Click here to add text. It is easy.
I am a paragraph. Click here to add text. It is easy.
I am a paragraph. Click here to add text. It is easy.
I am a paragraph. Click here to add text. It is easy.
I am a paragraph. Click here to add text. It is easy.
I am a paragraph. Click here to add text. It is easy.
I am a paragraph. Click here to add text. It is easy.
v
I am a paragraph. Click here to add text. It is easy.
bottom of page